• Leukemias, lymphomas, and other hematologic cancers

Aliqopa Generic Name & Formulations

General Description

Copanlisib 60mg; per vial; lyophilized pwd for IV infusion after reconstitution and dilution.

Pharmacological Class

Kinase inhibitor.

How Supplied

Single-dose vial—1


Generic Availability


Aliqopa Indications


In adults with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies.

Aliqopa Dosage and Administration


Give as IV infusion over 1hr. 60mg on Days 1, 8, and 15 of a 28-day cycle on an intermittent schedule (3 weeks on, 1 week off). Continue until disease progression or unacceptable toxicity. Moderate hepatic impairment (Child-Pugh B), concomitant strong CYP3A inhibitors: reduce to 45mg. Severe hepatic impairment (Child-Pugh C): reduce to 30mg. Dose modifications for toxicities: see full labeling.


Not established.

Aliqopa Contraindications

Not Applicable

Aliqopa Boxed Warnings

Not Applicable

Aliqopa Warnings/Precautions


Monitor for infection (eg, pneumonia); withhold if Grade ≥3 infection develops. Risk of serious pneumocystis jiroveci pneumonia (PJP); consider PJP prophylaxis for those at risks prior to initiation. Diabetes. Obtain optimal blood glucose and blood pressure (BP) control prior to each infusion; monitor closely. Discontinue if post-dose BP remains uncontrolled (>150/90mmHg) despite antihypertensives or elevated with life-threatening consequences. Monitor blood counts at least weekly during therapy. Monitor for non-infectious pneumonitis, neutropenia, severe cutaneous reactions, thrombocytopenia, other severe and non-life-threatening toxicities; see full labeling. Moderate or severe hepatic impairment. Embryo-fetal toxicity. Advise females of reproductive potential and males (w. female partners) to use highly effective contraception during treatment and for ≥1 month after the last dose. Pregnancy; exclude status prior to initiation. Nursing mothers: not recommended (during and for ≥1 month after the last dose).

Aliqopa Pharmacokinetics

See Literature

Aliqopa Interactions


May be antagonized by strong CYP3A inducers (eg, rifampin, St. John’s wort); avoid. Potentiated by strong CYP3A inhibitors (eg, itraconazole, grapefruit juice); if concomitant use unavoidable, reduce Copanlisib dose (see Adult).

Aliqopa Adverse Reactions

Adverse Reactions

Hyperglycemia, diarrhea, decreased general strength/energy, hypertension, leukopenia, neutropenia, nausea, lower respiratory tract infections, thrombocytopenia.

Aliqopa Clinical Trials

See Literature

Aliqopa Note

Not Applicable

Aliqopa Patient Counseling

See Literature